WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria.
“The persistent failure to develop, manufacture, and distribute effective new antibiotics is further fueling the impact of antimicrobial resistance (AMR) and threatens our ability to successfully treat bacterial infections,” says Dr. Hanan Balkhy, WHO Assistant Director General on AMR.
14103
近几十年来几乎所有投入市场的新型抗生素都是1980年代发现的抗生素药物类别的变体。
Almost all the new antibiotics that have been brought to market in recent decades are variations of antibiotic drugs classes that had been discovered by the 1980s.
14104
在资源有限的地区，在新生儿和幼儿等弱势群体中，抗微生物药物耐药性的影响最为严重。
The impact of AMR is most severe in resource-constrained settings and among vulnerable groups such as new-borns and young children.
14105
细菌性肺炎和血流感染是5岁以下儿童死亡的主要原因。
Bacterial pneumonia and bloodstream infections are among the major causes of childhood mortality under the age of 5.
14106
大约30%患败血症的新生儿死于对多种一线抗生素耐药的细菌感染。
Approximately 30% of neonates with sepsis die due to bacterial infectionsresistant to multiple first-line antibiotics.
WHO’s annual Antibacterial Pipeline Report, reviews antibiotics that are in the clinical stages of testing as well as those in early product development.
14109
报告评估了候选药物应对世卫组织《细菌类重点病原体清单》中概述的最具威胁性的耐药细菌的潜力。
The report evaluates the potential of the candidates to address the most threatening drug-resistant bacteria outlined in the WHO Bacterial Priority Pathogens List (WHO PPL).
14110
该清单包括13种重点耐药细菌，自2017年首次发布以来，为重点研发领域提供依据和指导。
This list, which includes 13 priority drug-resistant bacteria, has informed and guided priority areas for research and development since its first publication in 2017.